A Single-arm Single-center Trial of Bridging GPRC5D/CD3 Bispecific Antibody Treatment With BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma
Clinical trial NCT07185477 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07185477
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Status
- NOT_YET_RECRUITING
- Phase
- Early Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2025-09-15
- Primary completion
- 2027-05-31
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.